<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577625</url>
  </required_header>
  <id_info>
    <org_study_id>CSUB0176</org_study_id>
    <nct_id>NCT04577625</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics on Testosterone in Men</brief_title>
  <official_title>A Double-blind Randomized Clinical Study Investigating Lactobacillus Reuteri Supplementations Influence on Testosterone Levels in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGaia AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of L. reuteri ATCC PTA 6475 supplementation on testosterone&#xD;
      in men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The probiotic Lactobacillus reuteri ATCC PTA 6475 has been shown to modulate testosterone&#xD;
      levels in mice. It is not known if these effects are seen in humans and this trial is&#xD;
      intended to study this.&#xD;
&#xD;
      The aim of this study is to investigate if L. reuteri ATCC PTA 6475 will effect blood&#xD;
      testosterone levels in in healthy male subjects 50-65 years of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Actual">June 5, 2021</completion_date>
  <primary_completion_date type="Actual">June 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of total testosterone</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>Change in total testosterone concentration over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free testosterone index</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>Change in Free testosterone index (100x(Testosterone/SHBG) over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of hematokrit</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>Change in Hematokrit over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Continously 12 weeks</time_frame>
    <description>Adverse event from administration of first dose until 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>L. reuteri Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L. reuteri will be delivered in a capsule at a low dose including Vitamin D3. Administration twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L. reuteri High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L. reuteri will be delivered in a capsule at a high dose including Vitamin D3. Administration twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri (L. reuteri)</intervention_name>
    <description>L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only</description>
    <arm_group_label>L. reuteri High Dose</arm_group_label>
    <arm_group_label>L. reuteri Low Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to give signed informed consent for participation in the study.&#xD;
&#xD;
          -  Healthy males aged between 50-65 with no known underlying medical conditions&#xD;
&#xD;
          -  Subjects who are capable of taking themselves to testing centre at 3 separate&#xD;
             timepoints (Baseline, week 6 and week 12).&#xD;
&#xD;
          -  Subjects who are available to give fasting blood samples before 10am on day of blood&#xD;
             sample collection&#xD;
&#xD;
          -  No history of androgen or testosterone supplementation within 6 months prior to study&#xD;
             start.&#xD;
&#xD;
          -  Subjects who have not been taking antibiotics or probiotic supplements 4 weeks prior&#xD;
             to study start 8. Able and willing to comply with the restirictions defined for the&#xD;
             study period&#xD;
&#xD;
          -  Ability to understand and comply with the requirements of the study, as judged by the&#xD;
             investigator physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who presently have or have had cardiovascular issues in the past 2 years.&#xD;
&#xD;
          -  Subjects who have a Body Mass Index of &lt; 18 or &gt; 30&#xD;
&#xD;
          -  Known elevated Prostate Specific Antigen levels.&#xD;
&#xD;
          -  History of prostate or testicular cancer.&#xD;
&#xD;
          -  Nicotine abuse&#xD;
&#xD;
          -  Alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Health &amp; Society, Malmö University</name>
      <address>
        <city>Malmö</city>
        <state>Skåne</state>
        <zip>205 06</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

